RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:JPMYour other post was fine.
This one has gone too far.
NASH was not a fluke. I have been talking about for years after Doug Loe wrote about it. Why do you think he wrote about it? He heard about that opportunity from management and read up on the Grinspoon studies. TH had no money to fund those endeavours at the time.
Exercise in futility?
Expansion from 1 to 2 drugs? Acquisition of a cancer therapeutics company? NASH data to be parlayed in to cash flow? Expansion to Europe?
Sorry, this post is more a reflection of the stock price than of reality.
bfw
SABBOBCAT wrote: Garp, I am glad to hear from someone feeling the same frustrations as I am. NASH is a fluke and Grinspoon is the one leading the charge, not TH management. They need to demonstrate, with Trogarzo, that they are able to execute and deliver results. Without that TH will never get an appropriate valuation for the egrifta NASH opportunity. What other investors are seeing is a company that has a very interesting story and a management with good strategic instincts, but at the same time there is a clear lack of execution. Without sales, the whole endeavor feels like an exercise in futility.
SPECO, I do love your relentless optimism as it does help through these tough times